

14 September 2016

Update on Omniblend Innovation

Highlights

- Long-term trial results to be presented in Munich in September
- Television advertising to commence in late September
- 'Diet for Diabetes' educational seminars planned at RPA in Sydney on September 27
- MOU executed with Beijing Dongfang Hongsheng International Biotechnology Development Co. Ltd

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omniblend Innovation, the medical technology company focused on medical nutrition.

Further Validation through Ongoing Clinical Trials

The European Association for the Study of Diabetes annual meeting is taking place on 12-16 September in Munich, Germany. At the meeting, results of a clinical trial into the long term use of Omniblend Innovation's patented pre-meal drink, which is marketed in Australia as Faulding's GlucoControl™, will be presented. The independent study results presented will show that the use of GlucoControl™ over a long period of time can reduce the damaging blood sugar spikes and have a positive impact on Hba1c numbers for those living with type 2 diabetes. This is the first time that a pre-meal strategy has been shown to reduce HbA1c.

Trial results will also be presented in late October at Adelaide University.

Promotional and Educational 'Diet for Diabetes' Seminars

As part of its marketing program, Omniblend Innovation continues to hold promotional information sessions around the country for medical practitioners, pharmacists, dieticians and diabetes educators. The next event will be held at Royal Prince Alfred Hospital in Sydney on 27 September.

This event will include a panel discussion and Q&A session with Professor Peter Clifton, a prominent endocrinologist and Professor of Nutrition at the University of South Australia, Dr Ross Walker, one of Australia's leading preventative health experts who also has a weekly radio show on 2UE and appears regularly on other radio and television programs including the Today Show, A Current Affair and Sky News, Professor Jennie Brand-Miller, Professor of Human Nutrition at the University of Sydney who is known globally as "GI Jennie". Rounding out the panel will be Dr Gottfried Lichti, who serves as Director and Head of Research and Development at Omniblend Innovation.

Marketing Programs

Omniblend Innovation in conjunction with Faulding will commence a marketing campaign for GlucoControl™ in late September that will incorporate print, radio and television media.

Omniblend Innovation will also have a booth at the upcoming 120th China Import and Export Fair. The Fair will be held in Guangzhou, China in late October.

International Distribution

Omniblend Innovation has recently entered into a Memorandum of Understanding ("MOU") with Chinese company Beijing Dongfang Hongsheng International Biotechnology Development Co. Ltd ("DFHS"). The MOU provides the framework for the parties to enter into a definitive agreement on the registration, marketing and sales in China of GlucoSmooth™, Omniblend Innovation's pre-meal technology targeting people living with Type 2 Diabetes.

DFHS specialises in the health, supplement and wellbeing for the middle aged and elderly, supplying a range of services and products through its network to improve the quality of life in China. It has market knowledge, sales force capability and administrative capacity to facilitate import, distribution and sales of products like GlucoSmooth™ in China.

Omniblend Innovation is excited to formally commence the process of bringing its technology to the estimated 115 million Chinese people that have Type 2 Diabetes.

Ends

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omniblend Innovation

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In 2016 the Company launched its maiden product, Faulding's GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au